PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25796815-1 2014 UNLABELLED: Effectiveness of donepezil hydrochloride treatment for elderly patients with Alzheimer"s and vascular dementia types depending on the ApoE genotype. Donepezil 29-52 apolipoprotein E Homo sapiens 146-150 27716659-0 2017 Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. Donepezil 21-30 apolipoprotein E Homo sapiens 119-123 27716659-1 2017 The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms. Donepezil 25-34 apolipoprotein E Homo sapiens 145-149 27567841-0 2016 Butyrylcholinesterase K and Apolipoprotein E-e4 Reduce the Age of Onset of Alzheimer"s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. Donepezil 139-148 apolipoprotein E Homo sapiens 28-44 27567841-3 2016 OBJECTIVE: To validate candidate genes (APOE/BCHE) which display associations with age of onset of AD and donepezil efficacy in aMCI subjects. Donepezil 106-115 apolipoprotein E Homo sapiens 40-44 27567841-5 2016 (2005) study on vitamin E and donepezil efficacy in aMCI, we contrasted the effects of BCHE and APOE variants on donepezil drug response using the Alzheimer"s Disease Assessment Score-Cognition (ADAS-Cog) scale. Donepezil 113-122 apolipoprotein E Homo sapiens 96-100 27567841-8 2016 Among the carriers of APOE-e4 and BCHE-K*, the benefit of donepezil was evident at the end of the three-year follow-up. Donepezil 58-67 apolipoprotein E Homo sapiens 22-29 27567841-10 2016 CONCLUSIONS: APOE-e4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy. Donepezil 159-168 apolipoprotein E Homo sapiens 13-20 27282366-0 2016 Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer"s Disease: A Systematic Review and Meta-Analysis. Donepezil 63-72 apolipoprotein E Homo sapiens 25-29 27282366-2 2016 It remains controversial whether, and to what extent, individual variation in the genes responsible for drug metabolism (CYP2D6) or those associated with AD pathogenesis (APOE) modulate the response to donepezil treatment. Donepezil 202-211 apolipoprotein E Homo sapiens 171-175 27282366-3 2016 OBJECTIVE: The aim of this study was to better understand the potential link between donepezil treatment response and CYP2D6 or APOE polymorphisms. Donepezil 85-94 apolipoprotein E Homo sapiens 128-132 27207906-0 2016 Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. Donepezil 87-96 apolipoprotein E Homo sapiens 140-145 30349215-6 2018 In addition, the therapeutic response to donepezil may be influenced by apolipoprotein E or cytochrome P450 2D6 polymorphism. Donepezil 41-50 apolipoprotein E Homo sapiens 72-88 29605487-6 2018 Patients who were APOE E3 non-carriers and had the ABCA1 rs2230806 GG genotype tended to have a better clinical response to DNP therapy. Donepezil 124-127 apolipoprotein E Homo sapiens 18-22 27911294-9 2017 We observed similar interactions between BChE-K genotype and steeper changes in MMSE and CDR-SB scores in APOE4 carriers treated with donepezil compared to controls. Donepezil 134-143 apolipoprotein E Homo sapiens 106-111 27207906-6 2016 CONCLUSION: Our results indicate a synergistic action of Cerebrolysin and donepezil to increase serum brain derived neurotrophic factor and delaying cognitive decline, particularly in Alzheimer"s disease cases with apolipoprotein E epsilon-4 allele. Donepezil 74-83 apolipoprotein E Homo sapiens 215-241 26768225-2 2016 However, few studies have focused on the relationship between polymorphisms in apolipoprotein E and CYP2D6 (rs1065852) genes and therapeutic responses to donepezil (DNP). Donepezil 154-163 apolipoprotein E Homo sapiens 79-95 26768225-2 2016 However, few studies have focused on the relationship between polymorphisms in apolipoprotein E and CYP2D6 (rs1065852) genes and therapeutic responses to donepezil (DNP). Donepezil 165-168 apolipoprotein E Homo sapiens 79-95 26768225-6 2016 RESULTS: We found that ApoE E3 non-carriers responded better to DNP treatment than E3 carriers (p=0.000) and that CYP2D6*10/*10 patients (MMSE score change: 0.29+-3.27) exhibited better therapeutic responses to DNP than did CYP2D6*1/*1 and CYP2D6*1/*10 patients (p=0.033). Donepezil 64-67 apolipoprotein E Homo sapiens 23-27 26768225-7 2016 Patients who were ApoE E3 non-carriers and who had the CYP2D6*10/*10 genotype exhibited a trend toward better clinical responses to DNP therapy. Donepezil 132-135 apolipoprotein E Homo sapiens 18-22 26768225-8 2016 CONCLUSIONS: The ApoE E3 allele and the CYP2D6 rs1065852 polymorphism may provide clinically relevant information for predicting therapeutic responses to DNP therapy. Donepezil 154-157 apolipoprotein E Homo sapiens 17-21 26402762-7 2015 Both carriers and non-carriers of APOE-e4 who received donepezil experienced significant improvements from baseline in ADAS-cog score versus placebo (p < 0.05). Donepezil 55-64 apolipoprotein E Homo sapiens 34-38 26402762-8 2015 Change from baseline to final observation in the donepezil treatment group was - 2.95 for APOE-e4 carriers and - 4.09 for non-carriers (p = 0.23). Donepezil 49-58 apolipoprotein E Homo sapiens 90-114 25538729-0 2014 Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer"s Disease in China. Donepezil 118-127 apolipoprotein E Homo sapiens 81-85 25538729-1 2014 BACKGROUND/AIM: Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer"s disease (AD). Donepezil 203-212 apolipoprotein E Homo sapiens 147-163 25538729-1 2014 BACKGROUND/AIM: Recent data have indicated that the rs1080985 single nucleotide polymorphism (SNP) of the cytochrome P450 (CYP) 2D6 and the common apolipoprotein E (APOE) gene may affect the response to donepezil in patients with Alzheimer"s disease (AD). Donepezil 203-212 apolipoprotein E Homo sapiens 165-169 25796815-2 2014 THE AIM: To study the effectiveness of donepezil hydrochloride (Almer "Actavis") for elderly patients with Alzheimer"s and vascular dementia types depending on the ApoE genotype. Donepezil 39-62 apolipoprotein E Homo sapiens 164-168 25796815-4 2014 All patients have undergone clinical, neurological, laboratory, instrumental (electrocardiography, CT/MRI brain), neuropsychological examination, ApoE genotype determination RESULTS: Identified certain characteristics of response to treatment of donepezil hydrochloride (acetylcholinesterase inhibitor) with dementia according to ApoE genotype. Donepezil 246-269 apolipoprotein E Homo sapiens 146-150 25796815-6 2014 CONCLUSIONS: The effectiveness of the treatment of donepezil hydrochloride for elderly patients with dementia largely be associated with ApoE genotype available that makes it worthwhile carrying determine ApoE 2, 3, 4 allele in patients with cognitive deficits before starting pharmacotherapy. Donepezil 51-74 apolipoprotein E Homo sapiens 137-141 25796815-6 2014 CONCLUSIONS: The effectiveness of the treatment of donepezil hydrochloride for elderly patients with dementia largely be associated with ApoE genotype available that makes it worthwhile carrying determine ApoE 2, 3, 4 allele in patients with cognitive deficits before starting pharmacotherapy. Donepezil 51-74 apolipoprotein E Homo sapiens 205-209 23609381-5 2013 An increased donepezil plasma concentration [mean (SD), 75.14 (32.16) ng/mL] was significantly associated with the improvement of long-term memory (P = 0.045; odds ratio, 0.959; 95% confidence interval, 0.920-0.999) after adjusting for age, sex, education, and apolipoprotein E genotype. Donepezil 13-22 apolipoprotein E Homo sapiens 261-277 23950644-2 2013 There is also evidence that the common apolipoprotein E (APOE) polymorphism may affect the response to treatment with donepezil in Alzheimer"s disease. Donepezil 118-127 apolipoprotein E Homo sapiens 39-55 22986607-0 2013 Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer"s disease. Donepezil 62-71 apolipoprotein E Homo sapiens 24-28 22986607-1 2013 BACKGROUND: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer"s disease (AD). Donepezil 170-179 apolipoprotein E Homo sapiens 78-82 23950644-2 2013 There is also evidence that the common apolipoprotein E (APOE) polymorphism may affect the response to treatment with donepezil in Alzheimer"s disease. Donepezil 118-127 apolipoprotein E Homo sapiens 57-61 19738170-10 2009 Logistic regression analysis adjusted for age, sex, Mini-Mental State Examination score at baseline, and APOE demonstrated that patients with the G allele had a significantly higher risk of poor response to donepezil treatment (odds ratio 3.431, 95% confidence interval 1.490-7.901). Donepezil 207-216 apolipoprotein E Homo sapiens 105-109 20102379-0 2010 Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype. Donepezil 117-140 apolipoprotein E Homo sapiens 193-209 17452062-4 2008 Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE is an element of 4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. Donepezil 135-144 apolipoprotein E Homo sapiens 89-93 19595949-6 2007 In selected genotypes such as individuals with APOE e4, therapy with donepezil might slow progression. Donepezil 69-78 apolipoprotein E Homo sapiens 47-51 18401173-0 2008 Effect of ApoE genotype on response to donepezil in patients with Alzheimer"s disease. Donepezil 39-48 apolipoprotein E Homo sapiens 10-14 18401173-2 2008 In order to address this issue, we investigated the effects of ApoE genotype on the clinical response to donepezil in patients with mild to moderate AD. Donepezil 105-114 apolipoprotein E Homo sapiens 63-67 18401173-7 2008 CONCLUSION: AD patients who carry the ApoE epsilon4 allele may respond more favorably to donepezil than epsilon4 noncarriers. Donepezil 89-98 apolipoprotein E Homo sapiens 38-42 33251785-0 2020 Biophysical, Biochemical, and Behavioral Implications of ApoE3 Conjugated Donepezil Nanomedicine in a Abeta1-42 Induced Alzheimer"s Disease Rat Model. Donepezil 74-83 apolipoprotein E Homo sapiens 57-62 15829527-9 2005 Among carriers of one or more apolipoprotein E epsilon4 alleles, the benefit of donepezil was evident throughout the three-year follow-up. Donepezil 80-89 apolipoprotein E Homo sapiens 30-55 22034396-2 2004 Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Donepezil 72-81 apolipoprotein E Homo sapiens 319-336 22034396-2 2004 Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Donepezil 72-81 apolipoprotein E Homo sapiens 338-344 12142731-1 2002 The objective was to evaluate the effects of the apolipoprotein E (ApoE) genotype and gender on the response to donepezil treatment in Alzheimer"s disease. Donepezil 112-121 apolipoprotein E Homo sapiens 49-65 12142731-1 2002 The objective was to evaluate the effects of the apolipoprotein E (ApoE) genotype and gender on the response to donepezil treatment in Alzheimer"s disease. Donepezil 112-121 apolipoprotein E Homo sapiens 67-71 12007670-0 2002 ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Donepezil 50-59 apolipoprotein E Homo sapiens 0-4 12007670-8 2002 The present study provides evidence that donepezil influences APP metabolism in platelets, and suggests that ApoE genotype might be an important modulating factor for drug responsiveness in AD. Donepezil 41-50 apolipoprotein E Homo sapiens 109-113 16103669-0 2005 Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer"s disease. Donepezil 73-82 apolipoprotein E Homo sapiens 0-25 16103669-9 2005 We evaluated the possible effect of the APOE genotype on the neuropsychological tasks in relation to donepezil therapy. Donepezil 101-110 apolipoprotein E Homo sapiens 40-44 33383743-0 2020 ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood-Brain Barrier. Donepezil 72-81 apolipoprotein E Homo sapiens 0-4 33251785-8 2020 In the in vitro study, neurotoxicity induced by Abeta1-42 in human neuroblastoma (SH-SY5Y) cells was found to be significantly reduced upon treatment with ApoE3 donepezil nanoparticles. Donepezil 161-170 apolipoprotein E Homo sapiens 155-160 33251785-11 2020 From our observations, ApoE3 donepezil nanoparticles exhibited neuroprotection in the Abeta1-42 induced model by mitigating the pathological features and cognitive impairments. Donepezil 29-38 apolipoprotein E Homo sapiens 23-28 32237281-0 2020 Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil? Donepezil 138-147 apolipoprotein E Homo sapiens 27-43 32237281-1 2020 AIM: We investigated the associations of the single-nucleotide polymorphism rs1080985 of cytochrome P4502D6 (CYP2D6) and the apolipoprotein E (APOE) genotypes with cognitive and functional changes in patients treated with donepezil. Donepezil 222-231 apolipoprotein E Homo sapiens 143-147 32237281-7 2020 CONCLUSION: The CYP2D6 and APOE genotypes may modulate the effectiveness of donepezil on cognitive and functional status. Donepezil 76-85 apolipoprotein E Homo sapiens 27-31 31564952-0 2019 Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer"s disease and vascular dementia. Donepezil 81-90 apolipoprotein E Homo sapiens 36-40 31564952-1 2019 Purpose: This study aims to evaluate the influence of genetic polymorphisms of CYP2D6, CYP3A5, ABCB1, and APOE genes and nongenetic factors on steady-state plasma concentrations (Cpss) of donepezil and therapeutic outcomes in Thai patients with Alzheimer"s disease (AD) and vascular dementia (VAD). Donepezil 188-197 apolipoprotein E Homo sapiens 106-110 31418556-4 2019 In the present study, ApoE3 conjugated polymeric nanoparticles derived from diblock copolymer methoxy poly(ethylene glycol)-polycaprolactone (mPEG-PCL) have been used to boost the delivery of donepezil to the brain. Donepezil 192-201 apolipoprotein E Homo sapiens 22-27 31418556-7 2019 Donepezil-loaded polymeric nanoparticles were performed by using a nanoprecipitation method and further surface modified with polysorbate 80 and ApoE3 to increase the brain bioavailability and reduce the dose. Donepezil 0-9 apolipoprotein E Homo sapiens 145-150 31418556-11 2019 Orally administered ApoE3 polymeric nanoparticles resulted in significantly higher brain donepezil levels after 24 h (84.97 +- 11.54 ng/mg tissue) as compared to the pure drug (not detected), suggesting a significant role of surface coating. Donepezil 89-98 apolipoprotein E Homo sapiens 20-25